

Annual Report 2024

LIFERAFTGROUP.ORG



A Message from Our Executive Director

As I reflect on 2024, what stands out most is the strength and heart of this community. This year, we've continued to show up—for each other, for patients navigating GIST and other rare cancers, and for the future we're all working toward. One of our biggest steps forward was launching a new five-year Strategic Plan, setting a bold course rooted in the values we've always held: empowerment, patient-focus, innovation, and collaboration.

This report captures just some of what we've accomplished together, from expanding our advocacy efforts and strengthening our patient navigation, to raising awareness in new ways and deepening our collaborations with clinicians and researchers. These wins weren't just organizational milestones, they were moments that brought real help and hope to people when they needed it most.

Looking ahead to 2025, we know the road forward calls for creativity, urgency, and unwavering focus on what matters: improving lives and reaching for a cure. Our Strategic Plan is a guide, but it's the people in this community—patients, caregivers, partners, and supporters—who make the mission real. We're aiming higher, pushing harder, and keeping the patient voice at the center of everything. Thanks for being part of it all. Let's keep going together!

With appreciation,

Sara Rothschild



TABLE OF CONTENTS

4 Development & Involvement

6 Information, Education & Advocacy

8 Data Management & Research

12 TGCT Support/
GCT Support

14 Liposarcoma
Support Network

15 Donors

18 Board of Directors &
Medical Advisory Boards

DEVELOPMENT & INVOLVEMENT



The Development & Involvement (D&I) team serves as an integral unit of The Life Raft Group's mission, fostering support, education, and advocacy for patients and caregivers worldwide. Through global support groups, a robust mentoring program, and educational initiatives, the D&I team continues to build and strengthen a resilient GIST community. In addition to training mentors, the team leads fundraising efforts, including a GIST DO IT Walk, peer-to-peer campaigns, and events that sustain critical programs for those affected by GIST.



Bringing the Community Together: Life Fest 2024

One of the biggest highlights of the year was Life Fest 2024, held in July at the Signia Hilton Hotel in San José, California. Over 150 patients, caregivers, medical professionals, industry experts, and supporters gathered to learn, connect, and offer hope to one another. Attendees immersed themselves in educational sessions covering a wide range of informative topics. Beyond these sessions, participants engaged in meaningful small-group discussions, sharing personal experiences and offering mentorship and inspiration.



Fundraising & Community Engagement

The Life Raft Group's annual **Water of Life** whisky tasting fundraiser, hosted by Matt Lurin at Keens Steakhouse in New York City, drew nearly 50 enthusiastic supporters. This beloved event raised crucial funds to support GIST research and patient programs. As always, it was a night filled with camaraderie, education, and shared purpose. We look forward to expanding Water of Life events in 2025!



The steadfast support of our **Give Every Month (GEMs)** donors—now 40 strong—remains instrumental in sustaining our work. Additionally, a number of dedicated members continue to organize birthday fundraisers, demonstrating the collective power of small, consistent contributions in making a lasting impact.



CONTINUED ON PAGE 5

As we closed out 2024, The Life Raft Group launched an exciting new initiative: the **LRG Athletes Program**. This program is designed to empower individuals to achieve their athletic goals while supporting the GIST community. Whether running a marathon, cycling through rugged terrain, or participating in a personal challenge, LRG Athletes push their limits while raising awareness and critical funds for research, advocacy, and patient resources.



Expanding Patient Support & Education

Regular support group meetings continue to provide a vital space for members to connect, share, and find strength in a community that truly understands. Our **GIST Mentor Program** remains a lifeline for those navigating diagnosis and treatment. Since launching in 2019, the program has grown tremendously. In 2024, we proudly feature 42 mentors (U.S. & International) who have provided guidance and encouragement to over 300 mentees. The program thrives under the leadership of Santy DiSabatino, a dedicated patient advocate and LRG Board Member, alongside our Global Coordinator, Piga Fernández.

Recognizing the need for stronger regional leadership, the State Leader Program officially transitioned into our new **Regional Leader Program**. Many of our leaders now oversee multiple states, expanding their impact. Regional Leaders are an invaluable resource, helping patients and caregivers find local support groups, navigate resources, and connect with the broader GIST community.

Education remains a core focus of The Life Raft Group. In 2024, between in-person and virtual sessions, we hosted four GIST Days of Learning (GDOLs), reinforcing our commitment to accessible, expert-led education. These events provided cutting-edge insights and connected patients with leading GIST specialists. In-person GDOLs took place in Chicago in partnership with Northwestern University Feinberg School of Medicine, and in Columbus, Ohio, in collaboration with the Ohio State University Wexner Medical Center. Our virtual GDOLs were held in partnership Sylvester Comprehensive Cancer Center University of Miami Health and the University of North Carolina School of Medicine.



These events engaged hundreds of members of our community, strengthening knowledge and support networks across the GIST landscape. As we reflect on 2024, we remain steadfast in our mission to provide education, mentorship, and advocacy for the GIST community and beyond.

INFORMATION, EDUCATION & ADVOCACY



In 2024, The Life Raft Group remained committed to delivering impactful educational programs for patients and caregivers, empowering them to take a proactive role in their care and advocate for themselves. When patients are equipped with the latest insights from global GIST and sarcoma experts, they are more likely to ask informed questions, explore different treatment options, and chart a course toward the best possible care.

Our work is driven by the needs and voices of patients. Every webinar, educational outreach, and campaign is shaped by the conversations we have with patients about what matters most to them. We take pride in providing the information patients need in formats that are easy for them to access, knowing that this knowledge is crucial for their survival and well-being with GIST.

Webinars

The Life Raft Group partnered with experts in the field and patient advocates to host thirteen webinars in 2024. All webinars are available for patients to refer to on our website and YouTube channel. Topics and speakers of 2024 webinars were:

Gaining Insight on the INSIGHT Phase 3 Clinical Trial

Speaker: Dr. Neeta Somaiah,
MD Anderson Cancer Center
Date: April 11, 2024

How to Educate Yourself on GIST Research: Searching the Web for GIST Science Publications

Speaker: Jim Hughes, LRG Clinical
Trials Database Coordinator
Date: April 30, 2024

Demystifying Clinical Trials: Insights from Experts & Participants

Speaker: Dr. Candace Haddox,
Dana-Farber Cancer Institute and
Kandee Evans, GIST Patient Advocate
Date: May 22, 2024

Updates from ASCO

Speaker: Dr. Herber Loong,
Chinese University of Hong Kong
Date: June 18, 2024

GIST Awareness Day: A Focus on GIST Research

Speaker: Dr. Matthew Hemming and Favour Akabogu,
PhD Candidate of UMass Chan Medical School
Date: July 13, 2024

Managing Side Effects of GIST Therapies

Speaker: Dr. Mia Weiss, Washington University School
of Medicine in St. Louis
Date: August 19, 2024

Locoregional Therapies for Treatment of GIST in the Liver

Speaker: Dr. Edward Kim, Mount Sinai Medical Center
Date: September 9, 2024

IDRX-42: Trial Design and Emerging Data from the StrateGIST 1 Study

Speaker: Dr. Suzanne George,
Dana-Farber Cancer Institute
Date: October 7, 2024

Know Your Mutation: Why is Biomarker Testing Important in GIST?

Speaker: Dr. Calvin Chao and
Michelle Harris of Tempus
Date: November 6, 2024

GIST Updates from CTOS

Speaker: Dr. Thierry Alcindor,
Dana-Farber Cancer Institute
Date: November 25, 2024

CONTINUED ON PAGE 7

Biomarker Testing Campaign

The LRG strongly recommends biomarker testing for all GIST and sarcoma patients considered for drug therapy, provided that sufficient tumor material is available for testing. We have established close collaborations with leading GIST experts, whose work has highlighted the significant benefits of genomics-driven targeted treatments. Thanks to our commitment to testing, patients in the LRG registry have higher rates of biomarker testing and improved survival outcomes compared to the general patient population.

In 2024, The Life Raft Group brought together a diverse group of GIST Patient Advocates with lived experience to establish the LRG Health Equity Council (HEC). This marks a major step in our mission to provide every GIST patient with the resources and education they need not just to survive, but to thrive. The HEC, which currently has seven members, meets biweekly to research and develop strategies for engaging marginalized groups of GIST patients, ensuring they receive crucial information about biomarker testing. The Life Raft Group is confident that the formation of this council will significantly increase biomarker testing rates, particularly among our most vulnerable patients.

Additionally, The Life Raft Group continues to offer free biomarker testing to U.S.-based GIST patients through our partnership with Tempus.



DATA MANAGEMENT & RESEARCH



Data Management & Research has had an extraordinary year marked by groundbreaking achievements in advancing research, fostering global collaborations, and driving innovation to improve outcomes for patients with gastrointestinal stromal tumor. This report outlines our major accomplishments, including scientific contributions, conference presentations, strategic partnerships, and the establishment of transformative initiatives that position us as leaders in the field.

Scientific Contributions and Conference Presentations

Our department has actively engaged with the global scientific community, presenting pioneering research and collaborating with leading institutions and researchers to push the boundaries of GIST research. *Below are the key highlights:*

Posters Presented at Scientific Conferences

- 1. ASCO GI (American Society of Clinical Oncology Gastrointestinal Cancers Symposium) Characteristics and Predictors of Outcomes with Neoadjuvant Imatinib in Gastrointestinal Stromal Tumors: Real World Data from a Large Patient Registry**
This innovative study, conducted in collaboration with Dr. Udhayvir Grewal (University of Iowa), provided critical insights into treatment outcomes and predictors, contributing to the optimization of neoadjuvant therapy strategies.
- 2. ESMO (European Society for Medical Oncology) Real-world efficacy of imatinib in patients with advanced GIST: The LRG registry.** In partnership with Dr. Adrienne Victor and Dr. Gim Gahyun, this research highlighted real- world treatment efficacy, offering valuable data to inform clinical decision-making and improve patient outcomes.
- 3. GISTT Summit - Essen, Germany**
 - **Unlocking Insights: The Power of the LRG Patient Registry**
This presentation showcased the extensive capabilities of the LRG Patient Registry in driving research and unlocking actionable insights for the GIST community.
 - **Dual Mutations in SDH-Deficient GIST**
This study shed light on the complexity of SDH-deficient GISTs, providing a foundation for future research into dual mutations and their clinical implications.
 - The Life Raft Group was proud to be a Platinum Sponsor of this event.
- 4. CTOS (Connective Tissue Oncology Society)**
 - **D842V - A Tale of Two Stages: Comparative Analysis of Overall Survival and Treatment Response in GIST Patients with PDGFRA D842V Mutations** - This analysis offered a comprehensive understanding of the unique challenges and opportunities in treating patients with D842V mutations.
 - **Loss of PTEN Expression in MiniGISTs and Clinically Relevant GISTs** Conducted in collaboration with Dr. Joanna Przybyl (McGill University) and Dr. Xiaolan Feng (Tom Baker Cancer Center)
This study explored the molecular underpinnings of PTEN loss and its implications for GIST progression.


5. Additional Research

Predicting the Imatinib Response of PDGFRA Exon 18-Mutant Gastrointestinal Stromal Tumor Using In Vitro Models led by Dr. Michael Heinrich and Ph.D. candidate Homma Khosroyani (OHSU), this research leveraged cutting-edge in vitro models to predict treatment response, paving the way for personalized medicine approaches.

Speakers at Scientific Conferences

ASCO (American Society of Clinical Oncology) Denisse Evans, Senior Director of Data Management and Research, served as a distinguished faculty speaker, delivering a presentation on Leveraging Patient Engagement Through Collaboration for Improved Global Health Outcomes in Sarcoma. This work emphasized the importance of patient-centric approaches and cross-institutional partnerships in addressing disparities and improving outcomes in sarcoma care worldwide. This impactful presentation was followed by a chapter contribution to the ASCO Educational Book, developed in collaboration with Dr. Matias Chacon (Alexander Fleming Cancer Center) and Lynne Hernandez (Executive Director, Desmoid Tumor Foundation).

GISTT Summit - The GISTT Summit provided a comprehensive state-of-the-science review on GIST biology and treatment strategies while fostering collaboration among researchers, clinicians, industry, and advocacy groups to advance high-priority projects. Jerry Call, Data Analyst for The Life Raft Group, highlighted the challenges of overcoming resistance in GIST treatment. He noted a "Catch-22" where imatinib's success discourages innovation, despite tumors becoming more aggressive in later stages. Call stressed the importance of early intervention, especially for KIT-driven GIST, to improve outcomes and work toward a cure.



Strategic Partnerships and Initiatives

Establishment of SDH-Deficient Biobank and Centralized Database

In a landmark achievement, The Life Raft Group has partnered with the National Institutes of Health (NIH) and the University of California, San Diego (UCSD) to establish the SDH Biobank. Spearheaded by Dr. Andrew Blakely (NIH) and Dr. Jason Sicklick (UCSD), this initiative represents a transformative step in advancing research on SDH-deficient GIST. The biobank facilitates the collection, analysis, storage, and distribution of biospecimens, creating a centralized resource for researchers worldwide. This collaboration underscores our commitment to accelerating discoveries and fostering innovation in rare tumor research.



Data Collaborations

In 2024, we made significant strides in understanding GIST through strategic data collaborations, including valuable insights derived from our LRG Patient Registry, which now hold 2824 GIST patients from around the world. These partnerships have advanced our knowledge in several key areas:

- **Neoadjuvant Gleevec Studies:** Collaborations with leading institutions, supported by data from our patient registry, identified predictors of response and outcomes for neoadjuvant Imatinib (Gleevec) therapy, providing actionable strategies to optimize treatment plans.
- **SDH-Deficient Mutations:** Working with researchers from multiple institutions, we leveraged registry data to deepen our understanding of SDH-deficient mutations, uncovering their unique biological mechanisms and potential therapeutic targets.
- **Dual Mutations in GIST:** Collaborative studies, informed by patient registry data, explored the complexities of dual mutations, shedding light on their role in treatment resistance and disease progression.
- **Biomarker Identification:** Through global partnerships and data from our registry, we identified potential biomarkers for diagnosis and treatment efficacy, advancing personalized medicine approaches.
- **Imatinib Sensitivity Research:** Joint projects with academic institutions, utilizing registry data, enhanced our understanding of Imatinib sensitivity, refining therapeutic protocols to improve patient outcomes.
- **GIST Risk Collaboration:** A global working group of academic institutions collaborated to optimize risk tools for GIST patients. This effort aims to better characterize the risk of recurrence, providing more precise assessments to guide clinical decisions.

These collaborations, enriched by the data from our patient registry, highlight the power of collective expertise and shared resources, reinforcing our commitment to leveraging partnerships for groundbreaking discoveries and improved care.

LRG Virtual Tumor Board


In 2024, we hosted a LRG Virtual Tumor Board, uniting experts from multiple institutions to review a particularly complex GIST case. This multidisciplinary forum enabled in-depth analysis of treatment resistance and mutation profiles, fostering collaborative decision-making.

The session highlighted the value of shared expertise in addressing a challenging case and reinforced our commitment to advancing GIST research and improving patient care.

LRG Patient Membership and Educational Events

In 2024, we welcomed 309 new members to the LRG community, strengthening our network of patients, caregivers, and advocates. To educate and inspire our growing membership, we launched several impactful initiatives:

- "Let's Get the GIST of It" Series: This educational program focused on understanding GIST mutations, their role in the disease, and related topics such as clinical trials and pathology reports.
- "Clinical Trials Wednesday": A new initiative aimed at educating members about clinical trials, empowering them to explore innovative treatment options.
- Patient of the Month Stories: We highlighted the brave and empowering journeys of our patients, sharing their stories to inspire and connect our community.
- Free Tissue Testing Initiative: To ensure every patient receives mutational testing, we offered free tissue testing, providing critical insights for personalized treatment planning.



These efforts underscore our commitment to providing valuable resources, fostering education, and celebrating the resilience of the GIST community.

LRG PATIENT REGISTRY - Advancing the LRG Patient Registry

We are excited to share progress on our new and improved LRG Patient Registry platform, set to launch in 2025. This enhanced platform will integrate cutting-edge technology to provide patients with advanced tools for tracking and managing their GIST journey.

As part of the upgrade, we are optimizing the data fields we capture to include new features such as tumor evolution tracking, which will allow patients and researchers to monitor tumor response and progression over time. Additionally, the platform will include a user-friendly dashboard, enabling patients to easily view and update their health information while accessing personalized insights into their disease and treatment outcomes.

These enhancements reflect our dedication to leveraging innovation to empower patients, improve research efforts, and drive meaningful progress in the fight against GIST.

Rare Disease Initiatives Beyond GIST



This year, TGCT Support proudly marked its 5th anniversary! Over the past five years, we have overcome numerous challenges and touched the lives of countless patients. Guided by our mission to support those affected by TGCT and GCT, we have made remarkable strides in raising awareness and harmonizing the global management of these rare diseases.

In 2024, we achieved a groundbreaking milestone by analyzing, submitting, and presenting the first-ever patient-driven research project in TGCT. This project shed light on the unmet needs and challenges faced by patients navigating various healthcare systems. Additionally, we presented two impactful posters highlighting the patient experience with TGCT. Our efforts culminated in presenting this data as a podium talk at the Connective Tissue Oncology Society (CTOS) annual conference and submitting it for publication in a medical journal. Fueled by our passion, we initiated three additional research projects this year—and we're just getting started! Our support groups have grown to over 1,000 members from 48 countries, with six virtual groups designed to connect our geographically diverse community. We remain committed to providing accessible resources and fostering a global network of support for all patients, regardless of location.



Education has been another cornerstone of our work in 2024. We hosted three webinars, a TGCT Day of Learning (TDOL), and expanded our efforts internationally by hosting one patient conference session in Italy. These events brought together 40 patients in Italy and 60 in Colorado, showcasing the strength and unity of our community to providers and pharmaceutical partners. In a first for TGCT Support, we collaborated on a Continuing Medical Education (CME) course with PeerView, equipping healthcare providers with the latest advancements in TGCT management. Together, we have solidified TGCT Support as a vital resource for patients, providers, and researchers.

In the United Kingdom, we launched a groundbreaking initiative to develop referral criteria for patients with diffuse TGCT. By partnering with key opinion leaders, we aim to create a standardized approach to help patients navigate the NHS and ensure timely, multidisciplinary care. The positive response from UK providers highlights the significance of this effort and the resource challenges they face.



CONTINUED ON PAGE 13

Our commitment to raising awareness and amplifying the patient voice remains unwavering. We collaborate with stakeholders across sectors to ensure patients guide all activities, fostering a brighter future for those affected by TGCT.

As we celebrate these accomplishments, we also look forward to the future. The past five years have proven that our collective resilience, resources, and determination can change the course of this rare disease for the better.

Thank you to everyone who has supported us—your contributions fuel our mission. Together, we will continue to drive progress and make an even greater impact in the years to come.

Webinars

TGCT in the Youngest Patients

Speaker: Dr. Thomas Scharschmidt, Nationwide Children's Hospital Date: September 18, 2025

Navigating Insurance and Claims

Speaker: Monica Bryant, Triage Health Date: August 6, 2024

Educational Events - Day of Learning (TDOL)

TGCT Days of Learning are free, one day events for TGCT patients and their families to benefit from hearing important educational topics related to this rare disease, gain support from one another, and spend quality time with doctors who share cutting-edge disease information.

On July 27th, 2024, TGCT Support partnered with University of Colorado Anschutz Medical Campus to host a TGCT Day of Learning event. Over 70 patients and caregivers convened to engage with the TGCT medical community and learn about the latest treatment options, surgical information, orthopedic perspectives, and coping mechanisms.



www.tgctsupport.org



@tgctsupport3596



@tgctsupport



@tgctsupport



@tgctsupport

LIPOSARCOMA SUPPORT NETWORK

Since our launch in October, we have made remarkable strides in fulfilling our mission to connect, support, and empower liposarcoma patients and caregivers worldwide. We are proud to have welcomed members from across the globe and all sub-types of liposarcoma. This community underscores the universal need for resources and support for this rare disease.

During this time, we have had the privilege of connecting with many sarcoma specialists who share in our commitment to improving patient support and advancing awareness and research in the sarcoma community. As a result, partnering with Dr. Neeta Somaiah of MD Anderson for our first a webinar was pivotal in demonstrating our commitment to providing valuable resources and support to patients.

We are proud to have offered our first patient support group series to the liposarcoma community. This has quickly become a cornerstone of our efforts, offering a safe space for individuals to share experiences, exchange valuable insights, and foster meaningful connections.

In addition, we launched a comprehensive newsletter that highlights program updates, shares stories from our community, and delivers educational content tailored to our members' needs. The response to the newsletter has underscored its value as a resource for keeping our community informed and inspired.

Lastly, our commitment to raising awareness and sharing our work on a global scale led to the creation of a compelling poster that was showcased in the patient advocacy lounge at the 2024 Connective Tissue Oncology Society (CTOS) Annual Meeting. This opportunity not only highlighted our program's approach but also fostered collaborations with experts and organizations dedicated to advancing our shared goals.

As we reflect on these accomplishments, we are inspired by the resilience and enthusiasm of our community. Together, we have laid a strong foundation for continued growth and impact, and we look forward to building on this momentum in the coming year.

Our first educational webinar was:

Liposarcoma 101

Speaker: Dr. Neeta Somaiah, MD Anderson Cancer Center

Date: December 6, 2024



liposarcomasupport.org



[@LiposarcomaSupport](https://www.youtube.com/LiposarcomaSupport)



[@LiposarcomaSupport](https://www.facebook.com/LiposarcomaSupport)



[@liposarcomasupport](https://www.instagram.com/liposarcomasupport)



[@liposarcoma_sn](https://twitter.com/liposarcoma_sn)

Donor List

Our Funding Partners

\$78,000-\$202,000

Abbisko Therapeutics Co, Ltd.
Blueprint Medicines
Cogent Biosciences, Inc.
Daiichi Sankyo, Inc.
Deciphera Pharmaceuticals
IDRx, Incorporated

\$25,000-\$50,000

Genentech
Novartis Oncology
Peerview Institute

\$10,000-\$20,000

SpringWorks Therapeutics
Inhibrx
Virtue Research/Atlas Primary

\$5,000-\$10,000

EMD Serono, Inc.
SynOx Therapeutics
Novelty Nobility USA, Inc.

\$2,000-\$2,500

Newbay Pharmaceuticals
ICG Life Sciences
Fountain Healthcare
Aveo Pharmaceuticals, Inc.
SAI-Med Partners LLC
IPSEN

Our Donors

Over \$200,000

BST Consultants

\$20,000-\$100,000

Anonymous
Joan & Jim Nilmeler
Richard Becker

\$10,000-\$15,000

Birch Hill Equity Partners
Management Inc.
BNP Paribas USA, Inc.
Jerry Cudzil
Dolores Hawkins
Jim & Margi Hughes
Udvit Mehta
Gerald Knapp
Kay & Ira Stolzer

\$5,000-\$10,000

Dr. John Abrams
Lance Alspaugh
David Edraney
Helen Frey
Kamalesh Munirathinam
Deborah Spear
Friends of Kay Stolzer
Wes and Jacob Treder
Vinyl Destination

\$1,000-\$4,999

Behrooz Akbarnia
Jodi Alexander
Bank of America Matching
Iris Berke
Jill Biegansky
Georgia Bihr
Bill Borwegen
Paul Britton
Mark Caramatti
Ruchir Chandak
David & Maxine Clark
Lloyd Cuyler
Gina D'Amato
Max Jacobson & Helen
Degenhardt
Pete Dewalt
Eric & Kristy Dozier
Wilson Duong
Sean Finnegan
Saeed Foudeh
Dennis Genin
Thomas Green
Gerard Griffith
Bob & Louise Hammond
Peter Jacobson
Su Jitdumrong
Thomas Keller
Joy & Doug Knopp
Stelios Koutsoumbelis
Cathryn Kwart

Adam Levy
John Link
May Litt
Richard & Lisa Lowry
Ellen MacDonald
Camille Mayotte
Margaret McInteer
Greg & Karri Meehan
Carol Morris
Emily Pauley
Robert Perna
Christa Pereira
Alexander Robinson
Ellen Rosenthal
Melissa Ryan
Rodrigo Salas
Robert Sholiton
Anne Spar
Brent Staley
Lucina Stricker
Alice Sulkowski
Teren Family Charitable Fund,
American Endowment
Foundation
The Mia Byrne Charitable
Giving Fund
Jon P & Lori Treder
Donna-Maree Wilding
Dina Wiley
Martha Zielinski

\$500-\$999

Adobe Inc.
Erick Ammons
Olof Asbrink
Katie Babb
Boeing Company
Patricia Bonda Swenson
Katherine Brouse
Andrew Byer
Brian Carr
Rick Casey
Beverly Chalmers
Tim Clackson
John Culhane
Carolyn Dewalt
Julie Dicker
Santy DiSabatino
Roy Dyer
Pete Friello
Gayle Goff
Jing Goldsmith
PJ Greenan
Daniel Greenberg
Ksenia Griswold
Richard Harrington
Tyler Harris
Robert Haverkamp
Marian Hirsch
John Hunsucker
Jeffrey Johnson
Linda Karakousis
Ed & Alice Kondis
William Koontz

Caroline Lee
Pam London
Cynthia Marlow
Patrick McCarthy
Diane McGauran
Lisa & Eric Medhus
Karla Mertens-Morse
Microsoft Matching Gifts
Jonathan Miller
Andreas Musiol
Alex Nguyen
Alan & Cheryl Nichols
Kimberly O'Rourke
Irene Pedraza
Natalie Power
Cynthia Russell
Jennifer Sangillo
Jennifer Sedlis
Wanda Sebestin
Giacomo Selloni
Andrew Shih
Nancy Smith
Michael St. James
Robert Taylor
Victoria Thomas
Ryan Tickner
Mark Vieha
Michael Wallace
Michael Williams
Rebecca Wong
Hans Wyss
Kurt Zyla

\$100-\$499

Malcolm Airst
Diane Albrecht
Zackaria Ali
Iain Allan
Rusul Almarayaty
Ashwini Anburajan
Heather Anderson
Vicki Anderson
Kay Asher
Deborah Audley
Jan Xavier Avellano
Brian Baggett
Connie Baney
Chris Bayard
Jules Bender
Paul & Joanne Benoit
Grant Birkinbine
Betsy Bisno Phillips
William Bittar
Noel Bleakney
Helen Bock
Rich Bonner
Julie Bottomley
Phyllis & Richard
Boudreau
William Bough
Emily Bowden
Neil Boyd
Beatrice Bradford
Simon Brooking
Shawn Brown
Alexandra Buchanan
Ashley Bunch
Charles Burke
Jonathan Bush
Cheryl Calame
Jerry Call
Deci Call
Kelly Canepa
Rick Carrera
Rene Carrillo
Thomas Carson
Cheryl Cass
Chevron Matching
Sharon Clarke
Jeannette Cline
Andrew Colman
Valerie Combs

Robert Cook
Maureen Cosyns
Daniel Crowell
Simone Dahl Curi
Karen & Rauf Dalal
Bettina Darveaux
Jeffrey Davis
Floencia De La
Torre-Stevenson
Evelyn De Mello
Katherine Degrow
Rhonda Deimer
Michelle DeValera-Gibson
Stephanie Diaz
Nicole Dominiak
Donna Dovoric
Maureen Dressler
John Driscoll
Duke Energy
Julianne Duncan
Sally Edelman
Alicia Eppler
Steven Ethier
Cynthia Faust
Laurie Feingold
Jane Fischer
John & Janet Flood
Robert Focht
Anne Fogarty
David French
Barbara Frisch
Dan Frisch
Lisa Fues
Renee Garske
Linda Geiss
Terry Giles
Rachel Gillespie
Sheryl Ginsberg
GitHub
Eileen Glasser
Eleanor Glover
Abby Goodman
Linda Goodman
David Gordon
Linda Gosser
Charlie Grana-Benn
Eric Hamilton
Dana Hamry
Kate Hanley

Charley Harden
Jany Hatanaka
David Hayes
Accessia Health
Curtis Henry
Janet Hines
Valerie Ho
Allison Hogan
Jen Horan
Zach Howes
Jennifer Hoyer
Joseph Hyman
Instyle Hair Designs, Inc.
Joanne Isaac
Betty Jensen
Patrick Johnson
Lori Johnson-Berger
Jennifer Jolin
Michael Josephy
David Josephy
Irene Josephy
Alexis Kaiser
Angela Kang
Jan Kaprielian
Irving Kass
Derek Kaufman
Pamela Kepple
Victoria Kessler
Amanda Kiesewetter
Heemin Kim
Luda Kirschenbaum
Marlin Kirshenbaum
Mark Klizas
Mike Kologinski
Lynn Kravitz
Rochelle & Howard
Kristol
Jamie Lafata
Megan Lafollette
Cynthia Lavo
Micheal Leary
Wei Fen Lee
Robert Lemeshka
Jodi Levin
Sheila Levine
Jeffrey Lichtman
Ariel Lim
John Lim
Robert Little

Dan Loeser
Tann Ting Loh
Mike Lopane
Indra Lovko
Jillian Lye
Michelle MacLea
Annalucia Maisto
Hannah Marcus
Lora Marden
Maritza Marmolejo
Mariam Massarat Foudeh
Jacqueline Matlow
David Matlow
James McCallister
Sam McCandless
Michael McDermott
Nila McDonald
William Medina
Emily Meyer
Karen Meyers
Mark Miller
Donna Mizuno
Margaret Mlachak
Claire Monaghan
Sheri Mongeau
Jennifer Moore
Richard Morello
Maureen Murray
Mark Murray
Jayne Nicki
Rachel Nisanholtz-Gannot
Charlyn Nolander
Craig W & Connie K
O'Reilly
Virginia Ossio
Rich & Becky Owens
Victor Ozeri
Anne Pacifico
Rick Paczewski
Theodore Pak
Daisy Pang
Glenn Pasiewicz
John Perkins
Dena Petersen
Ellen Peterson Esser
Lisa Pike
Jessica Pohle
Lisa Pope
Aimee Powell

Yash Prakash
Merry Ann Pratt
Lisa & Bill Rappoport
Loren Ratner
Robert Rea
Nick Rich
Chris Riesbeck
Keisha Roberts
Raj Sabharwal
Aniello Sarno
Dave Schmier
Susan Schmitt
Stephen Schuler
Susan Schwab
Jessica & Bruce Schwartz
Nichole & Jim Schweppe
Brandon Seah
Meaghan See
Elizabeth Short
Lawrence Singer
Kuldev Singh
Elizabeth Skree
Zak Sobel
Peter Stark
David Stegmeir
Luis Steuer
John Stinson
John Surritte
Megan Tallmer
Nadine Tanenbaum
Kimberly Taylor
The Trade Desk
Thrivent
TIAA
Vicki Tomlin
Carolyn Tordella
Alison Truong
Sara Turner
United States Naval
Academy
Cheryl VanDeKerkhove
Vanguard Brokerage
Angela Vitorino
Dianne G Wadley
Anne Wasem
Roger Webber
Michael Weinberg
Carol Weinschel
Lisa Welch

\$100-\$499 cont.

Jennifer Werner
Lynn Whelan
Dawn White
Rachel Wilborn
Martina Will
Bea Williams
Danielle Williams
Abigayle Williams
Ken & Nanci Witten
David Wolfe
Ellen Woo
Julia Wood
Beth Young
Karen Young
Brandon Zaring

\$0-\$99

Novelyn A. Williams
Emiliano Acuna
Leah Afshar
Miguel Aguilar
American Express
Matching
Susan Anderson
Monica Anderson
Danielle Baham
Samuel Barry
Elizabeth Bartek Nosie
Luann Bartke
Natalie Baumann
Janette Belanger
Janet Blum
Melissa Bodin
Greta Boye
Kati Brock
Stephanie Bryant
Barbara Bukanowska
Reva Burchett
Byambajav Buyandelger
Rita Campbell
Pam Canon
Bob Cappello
Mj Cavanagh
Diana Chen
Justin Chen
Rachel Clarkin-Breslin
Katherine & Roger Clemons
Erica Connolly
atricia Cornelius
Ron Cotoni
Gwen & Jon Cummings
Hilary D'Anna
Cecilia D'Souza
Carol Danoff
Karen Dalal
Melissa Dominguez
Piotr Drozd
Catherine Dunn
Brianna Enciso
Cindi & Jim Fabricant
William Fialko
Heidi Francis
Niekia Franklin
Pamela Fry
Linda Gabel
Roger Goldberger

Julia Góral
Amy Gordon
Samantha Greenberg
Rhonda Greifinger
Mildred Guzman
Sarah Haddix
Robert Hammond
Debbie Harary
Michael Heinrich
Rick & Jodi Hicks
James Hilker
Steve Hoyer
Cole Hypes
Philip Ip
John & Mary Lu Jackson
John Jackson
Bartosz Jacyna
Christy Jaworski
Xin Jin
Debbie Johnson
Emily Johnson
Rob Jolin
Emily Jonczak
Lisa Jones
Sandy Kaslow-Briggs
Elissa Kaufman
Susan Kiudulas
Richard & Beth Klein
Glenn & Susan Kornreich
Peggy Korte
Roman & Mandy Kulik
Wendi Lax
Micheal Leary
Shannon Lehn
Jody Lenington
Steven Levinson
Denise Lynch
Dave Mackenzie
Jacqueline Malliet
Owen McFadden
McKinsey
Elizabeth McKune
Tim & Tammi Mengel
Lindsey Meyers
Mistee Montanye
Brian Morello
J.D. & Catherine Murphy
Orinder Nagra
Florentina Negoita

Carrie Nellis
Elizabeth Nelson
Melisa Neri
Latasha Nisbett
Erin Noguess
Dianne Nola
Laura Occhiuzzi
Gretchen Ogerly
OneHope Foundation
Ted Opderbeck
Bianca Ozeri
Joanna Panizales
Rachel Parnes
Christine Pasquesi
Amanda Pekny
Cecilia Perez
Katherine Perreth
Kimberly Peters
L Dena Petersen
Kyle Peterson
Jasmin Peterson
Claudette Pfennig
Nicole Pierce
Helen Prince
Anne Quek
Arlene Quezada
Michael T Quinn
Catherine Riker
Larry Robertson
Raul Rodriguez
Rigo Rodriguez
Kathryn Romanek
Amber Santiago
Gary Sather
Lauren Scholz
Deborah Silverstein
Martha Smart
Laverne Smith
Maryanne Soh
Stefanie Solomon
Andrea Sommer
Susan Spivack
Sheryl Spray
Sharon Stein
Samuel Steinfeld
Julia Takhushva
Tim Tate
Virginia Terrebonne

Ellen Thomson
Elissa & Kendra Tobes
Michelle Tobias
Jill Turner
United Way-Plymouth
Community
Donna Vesely
Ivan Vianna
Renee Villaire
Elyse Walker
Amanda Watts
Mike Wenner
Karla Westerfield
Christina Wilson
Lindsey Wolters
Sonia Wykes
John Yakubov
Xiyue Zao
Limin Zhu

Board of Directors

Gary Glasser Board President	Steve Pontell Vice President	Santy DiSabatino Treasurer	Kay Stolzer Secretary	Jerry Cudzil Past President
--	--	--------------------------------------	---------------------------------	---------------------------------------

Dr. John Abrams Dr. Monica Anderson Bill Borwegen Stan Bunn Dr. Joe Germino Jim Hughes
Christa Pereira Teena Petersohn Patricia Bonda Swenson

Medical Advisory Board - GIST

Andrew M. Blakely, MD National Institutes of Health	Michael C. Heinrich, MD OHSU Knight Cancer Institute	Sameer Rastogi, MD All India Institute of Medical Sciences	Peter Reichardt, MD Helios Klinikum Berlin-Buch
Gary Schwartz, MD Case Comprehensive Cancer Center	César Serrano García, MD Vall d'Hebron Institute of Oncology	Jason Sicklick, MD UCSD Moore's Cancer Center	Neeta Somaiah, MD MD Anderson Cancer Center
			Jonathan Trent, MD Sylvester Comprehensive Cancer Center

Medical Advisory Board - TGCT Support

William D. Tap, MD Memorial Sloan Kettering Cancer Center	R. Lor Randall, MD, FACS UC Davis Comprehensive Cancer Center	Thierry Alcindor, MD, MSc Dana-Farber Cancer Institute	Nicholas Bernthal, MD UCLA Health	Sebastian Bauer, MD West German Cancer Center University Hospital Essen
Silvia Stacchiotti, MD IRCCS Istituto Nazionale Tumori	Hans Gelderblom, MD Leiden University Medical Center	Richard Reidel, MD Duke Cancer Center	Vivek Bhadri, MA, MBBS, PhD, FRACP Chris O'Brien Lifehouse	

Medical Advisory Board - Liposarcoma Support Network

Gregory Cote, MD, PhD Mass General Cancer Center	B. Ashleigh Guadagnolo, MD, MPH MD Anderson Cancer Center	Mrinal Gounder, MD Memorial Sloan Kettering Cancer Center	Julie Grossman, MD University of Miami Health System	Emily Jonczak, MD University of Miami Health System
Alessandra Maleddu, MD University of Colorado Cancer Center	Jason Sicklick, MD UCSD Moore's Cancer Center	Arun Singh, MD UCLA Santa Monica Cancer Center	Neeta Somaiah, MD MD Anderson Cancer Center	Inga-Marie Schaeffer, MD Harvard Medical School - Brigham & Women's Hospital
		William Tseng, MD City of Hope		